Affiliation:
1. IRCCS Fondazione Ca' Granda - Ospedale Maggiore Policlinico
2. University of Milan
3. Humanitas University
Abstract
Abstract
Background: Bronchiectasis is characterized by neutrophilic inflammation and frequent exacerbations often associated with infections. Lipid mediators play critical roles in the inflammatory response, the balance between anti-inflammatory and pro-inflammatory mediators could drive to chronic inflammation. The aim of this study was to evaluate the metabolite of docosahexaenoic acid and arachidonic acid in sputum of adults with bronchiectasis defining their associations with clinical data, bacterial load and neutrophil elastase.
Methods: An observational, cross-sectional study was conducted at the bronchiectasis program of the Policlinico Hospital in Milan, Italy, where patients were enrolled. Active neutrophil elastase was measured by enzyme-linked immunosorbent assay, pro-resolving and pro-inflammatory fatty acid-derived mediators were evaluated by mass spectrometry and respiratory pathogens were carried out through real-time PCR. Analysis were performed on sputum collected during stable state and clinical data were also collected.
Results: Levels of pro-inflammatory mediators derived from arachidonic acid metabolism showed association with neutrophil elastase, were proportional to Pseudomonas aeruginosa identifications and were linked with radiological gravity index, while the concentrations of pro-resolution mediators derived from docosahexaenoic acidwere associated with a better health status highlighted by the inverse correlation with radiological gravity index, bacterial infections and sputum volume production.
Conclusion: Taking into account the clinical need to identify treatable traits in bronchiectasis useful to reduce exacerbation, lung infections and inflammatory reactions, could be helpful understand the role of pro-inflammatory and pro-resolving mediators derived from FA metabolisms in the modulation of these reaction. These information could be used to plan a personalized approach to try to reduce the symptoms of the disease.
Publisher
Research Square Platform LLC
Reference31 articles.
1. Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017. doi: 10.1183/13993003.00629-2017
2. The biology of pulmonary exacerbations in bronchiectasis;Amati F;Eur Respir Rev,2019
3. Inflammation: a two-edged sword–the model of bronchiectasis;Cole PJ;Eur J Respir Dis Suppl,1986
4. Antimicrobial peptides, disease severity and exacerbations in bronchiectasis;Sibila O;Thorax,2019
5. Neutrophil elastase in bronchiectasis;Gramegna A;Respir Res,2017